Lataa...
Ofatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrat...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3513208/ https://ncbi.nlm.nih.gov/pubmed/23226042 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|